Poxel’s Phase II Data Add AMP Kinase Activation To NASH Possibilities
Executive Summary
Recent development upheaval in non-alcoholic steatohepatitis has created opportunity for new approaches, and Poxel thinks its AMPK activator may address several NASH-related pathologies.
You may also be interested in...
Genfit Not Fully Exiting NASH, Despite Terminating RESOLVE-IT
A fuller look at interim Phase III data shows no path forward to accelerated approval in NASH, company says. Genfit turns focus to developing elafibranor for PBC, as well as a NASH diagnostic.
Intercept’s CRL Just Continues Upheaval In NASH
With approval timeline for OCA now thoroughly unclear and Genfit on the ropes, might the top spot in NASH end up with Galmed, AbbVie, Madrigal, Inventiva or Gilead instead?
Poxel Adds To NASH Pipeline With Novel Single-Isomer Pioglitazone
Some ground-breaking chemistry has been used to produce a single isomer of pioglitazone, which has been acquired by France's Poxel to evaluate in NASH, adding to its portfolio of potential metabolic disease therapies.
Need a specific report? 1000+ reports available
Buy Reports